Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case

Surg Today. 2012 Nov;42(11):1096-9. doi: 10.1007/s00595-012-0134-8.

Abstract

This report describes the laparoscopic resection of a rectal GIST after treatment with imatinib mesylate. A 56-year-old male presented with a submucosal tumor (longest diameter, 8 cm) arising in the lower rectum. A core needle biopsy revealed that the tumor contained bundles of spindle-like cells. Immunostaining revealed that the tumor was positive for c-kit and CD34. Analysis of the c-kit gene revealed a substitution of ACA (threonine) by GCA (alanine) at codon 574 of exon 11. Imatinib mesylate (400 mg/day) was given as preoperative adjuvant therapy for 3 months, and the tumor shrank to 5 cm in diameter. Proctectomy with transanal anastomosis could be performed laparoscopically, while preserving the anus. There was no evidence of recurrence 2 years 6 months after surgery. Preoperative adjuvant chemotherapy with imatinib mesylate may permit the use of less invasive treatment procedures, allowing anal preservation.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Benzamides
  • Biopsy, Fine-Needle
  • Colectomy / methods
  • Follow-Up Studies
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery*
  • Humans
  • Imatinib Mesylate
  • Immunohistochemistry
  • Laparoscopy / methods*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Piperazines / administration & dosage*
  • Preoperative Care / methods
  • Pyrimidines / administration & dosage*
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / surgery*
  • Risk Assessment
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate